Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-1950
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update ; volume:78 ; number:1 ; day:29 ; month:11 ; year:2017 ; pages:19-37 ; date:1.2018
Drugs ; 78, Heft 1 (29.11.2017), 19-37, 1.2018

Klassifikation
Medizin, Gesundheit

Urheber
Nijhof, Inger S.
Beteiligte Personen und Organisationen
Donk, Niels van de
Zweegman, Sonja
Lokhorst, Henk M.
SpringerLink (Online service)

DOI
10.1007/s40265-017-0841-y
URN
urn:nbn:de:101:1-2018061321200705384368
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:26 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Nijhof, Inger S.
  • Donk, Niels van de
  • Zweegman, Sonja
  • Lokhorst, Henk M.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Management of Relapsed and Refractory Multiple Myeloma: Recent advances

Management of Relapsed and Refractory Multiple Myeloma: Recent advances

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Update on the management of relapsed/refractory chronic lymphocytic leukemia

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

Verbundene Objekte